Compare Infosys Limited (INFY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Spyre Therapeutics Inc. Common Stock — how do they compare? Infosys Limited trades at $11.76 (market cap $46.25B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Infosys Limited is far larger — about 6.3× Spyre Therapeutics Inc. Common Stock's market cap, and Infosys Limited pays a 4.56% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| INFY | SYRE | |
|---|---|---|
Market Cap | $46.25B | $7.35B |
Volume | 14,209,421 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $20.22 | $108.92 |
52-Week Low | $10.49 | $22.18 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $44.00B | $6.35B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal and strong profitability metrics including a 16.37% net margin and 32.12% ROE. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, signaling growth initiatives.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering modest upside. Risks include potential earnings volatility and competitive pressures in IT services. Analyst sentiment is mixed with 35% buy ratings, but strong cash flow and institutional interest support a stable investment case amid sector headwinds.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
